Assertio Holdings (ASRT) Cash from Financing Activities (2019 - 2026)

Assertio Holdings' (ASRT) quarterly Cash from Financing Activities came in at -$189000.0 in Q1 2026, down 70.27% year-on-year from -$635727.3 in Q1 2025, and down 9350.0% quarter-over-quarter from -$2000.0 in Q4 2025.

Assertio Holdings (ASRT) Cash from Financing Activities (2019 - 2026) Analysis & Trends

Assertio Holdings has disclosed Cash from Financing Activities across 8 years of filings, most recently posting -$189000.0 for Q1 2026.

  • Cash from Financing Activities for Q1 2026 came in at -$189000.0, down 70.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$267000.0 (down 4.71% YoY), and the FY2025 annual result was -$189000.0, up 46.0% from the prior year.
  • Cash from Financing Activities came in at -$189000.0 for Q1 2026 at Assertio Holdings, down from -$2000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $2.9 million in Q3 2022 to a low of -$19.0 million in Q1 2023.
  • The 5-year median for Cash from Financing Activities is -$111000.0 (2025), against an average of -$3.1 million.
  • Across the five-year window, Cash from Financing Activities jumped 911.24% in 2022 and slumped 1017.17% in 2023, its largest moves.
  • Assertio Holdings' Cash from Financing Activities stood at -$798000.0 in 2022, then plunged by 1017.17% to -$8.9 million in 2023, then soared by 99.34% to -$59000.0 in 2024, then jumped by 96.61% to -$2000.0 in 2025, then tumbled by 9350.0% to -$189000.0 in 2026.
  • The last three Cash from Financing Activities figures came in at -$189000.0 (Q1 2026), -$2000.0 (Q4 2025), and -$7000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 13.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -840.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -1.48 Bn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -86.10 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -65.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 1.47 Bn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -77.88 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn -11.62 Mn
10 Assertio Holdings 150.94 Mn 79.37 Mn 7.22 Mn -189,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -189,000.00
Mar 31, 2026 -189,000.00
Dec 31, 2025 -2,000.00
Dec 31, 2025 -2,000.00
Sep 30, 2025 -7,000.00
Sep 30, 2025 -7,000.00
Jun 30, 2025 -69,000.00
Jun 30, 2025 -69,000.00
Mar 31, 2025 -111,000.00
Mar 31, 2025 -111,000.00
Dec 31, 2024 -59,000.00
Dec 31, 2024 -59,000.00
Sep 30, 2024 -10,000.00
Sep 30, 2024 -10,000.00
Jun 30, 2024 -75,000.00
Jun 30, 2024 -75,000.00
Mar 31, 2024 -206,000.00
Mar 31, 2024 -206,000.00
Dec 31, 2023 -8.92 Mn
Dec 31, 2023 -8.92 Mn